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OBJECTIVES: In Uganda, mother to child transmission (MTCT) of HIV is responsible
for approximately 25,000 infections among newborns annually and is the third
leading cause of new infections. This analysis attempts to quantify the financial
and disease burden associated with MTCT of HIV in Uganda. METHODS: Whereas
HIV-negative infants have a life expectancy at birth ranging from 52.2 years for
males and 54.3 years for females, the life expectancy of HIV-positive infants varies
from 2 years in the absence of antiretroviral therapy (ART) to about 14.2 years with
ART. Approximately 18% of eligible children in Uganda have access to ART, at an
annual treatment cost of US$328. Lifetime health-care costs of HIV-positive un-
treated infants are assumed to be US$495. The model calculates years of life lost
(YLL) as the difference in life-expectancy between HIV-positive and HIV-negative
newborns and years of life lived with disability (YLD) by applying the relevant
disability weights of 0.123 for each year lived with HIV and 0.5 for the last year of life
with AIDS. All costs and life years are discounted at 3% annually. RESULTS: The
total annual disease burden resulting from mother to child transmission of HIV is
estimated at 592,480 disability adjusted life years (DALY’s), which is defined as the
sum of YLL: 572,662 and YLD: 19,818. The discounted net present value of future
health care costs associated with mother to child transmission of HIV is estimated
at US$27.3 Million. CONCLUSIONS: Mother to child transmission of HIV is associ-
ated with a substantial mortality and morbidity burden in Uganda. The financial
burden is also worrisome in a country with annual health expenditures of US$24
per capita (circa US$ 830 Million total). Cost-effective strategies to reduce the inci-
dence of MTCT that can be scaled-up nationally are urgently needed.
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OBJECTIVES: To determine the cost of non-CF bronchiectasis patients enrolled in a
managed care plan. METHODS: Data were obtained from a large employer-based
claims database. A cohort of bronchiectasis patients (cases) with and without acute
exacerbations was identified using ICD-9 494.0 and 494.1 codes and matched (1:3)
on demographics to those without the disease (controls) from January 1, 2005-
December 31, 2009. Index event for cases were defined as the first medical claim of
bronchiectasis during the study period and controls were assigned the same index
event to whom they were matched. Cases had no medical claim for cystic fibrosis
and chronic obstructive pulmonary disorder 12 months prior (baseline) and post
index event. Medical resource use and expenditures were estimated for 12 months
before and after index event. All statistical tests were conducted using SAS 9.2.
RESULTS: The final study sample included 9,146 cases and 27,438 matched con-
trols. 64% and 50% of the sample was females and between 45-64 years of age at
index date, respectively. 37%, 29%, and 27% of the sample was enrolled in a POS,
HMO, or PPO type of health plan. Overall comorbidity burden as measured by the
Charlson comorbidity score and respiratory conditions other than bronchiectasis
were significantly (p.001) greater at baseline among cases vs. controls. The incre-
mental overall ($2,128 vs. $783) and respiratory-related ($896 vs. $100) costs were
significantly (p.001) greater among cases vs. controls. The difference was primar-
ily driven by an increase in outpatient care visits (2.21 vs. 0.43), emergency room
visits (0.31 vs. 0.08) and pharmacy scripts (3.58 vs. 0.83) in the post-index period vs.
baseline in cases vs. controls. CONCLUSIONS: The study found that overall incre-
mental economic impact of non-CF bronchiectasis to a health plan was $1345 per
patient. Further research needs to identify the impact of current treatment on the
burden of the disease.
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OBJECTIVES:To analyze the changes in the antiretroviral pharmacotherapy during
2006-2010 and its impact on cost and disease control of HIV/AIDS patients in
Bulgaria.METHODS:Micro costing approach was used based on retrospective anal-
ysis of patients’ records in major clinic for immunosuppressed patients at the
University hospital of infectious and parasitic diseases in Sofia. Information was
gathered for the way of diseases transmission, antiretroviral combinations and
their cost, CD4 count and viral load per patient per year. It was evaluated the
changes in the dosage regimes, cost of therapy and its influence on CD4 count and
viral load. RESULTS: On total 162 patients were included in the study. Nearly 40
different dosage regimes were identified and all of them are combinations of 3 or 4
medicines. During the period were introduces 3 new antiretroviral medicines
(tenofovir, emtricitabin, darunavir). The average yearly cost of pharmacotherapy
(all regimes and patients) is increasing from 155 837.64 euro to 319 571.76 euro
during 2006 - 2010 due to switch of the therapy for some of the patients to newer
medicines because of drug toxicity, resistance or other reasons. All newly regis-
tered patients are treated with the new antiretroviral products and their yearly cost
of therapy is 178251.12 euro. Introduction of the new medicines led to the increase
in total pharmacotherapy cost with 291 89.64 euro, but also to better control mea-
sured with the increase in CD4 count (500) and sustained suppression of vial load
to 20 in 45.46% of patients. CONCLUSIONS: HIV/AIDS remain costly diseases for
the Bulgarian population but new medicines led to better control on its progress
and thus could save further hospital cost.
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OBJECTIVES: Respiratory syncytial virus (RSV) is increasingly recognized as an
important cause of morbidity, mortality and health-care resource use in the el-
derly. Therefore we determined whether there are specific levels of vaccine cost
and effectiveness for which a hypothetical RSV-vaccine for Dutch elderly could be
cost-effective.METHODS: The annual excess RSV-associated age- and risk-specific
burden was estimated using a rate-difference method. Different vaccination strat-
egies were evaluated, for various levels of vaccine effectiveness and different levels
of willingness to pay per quality-adjusted life year gained (QALY). Outcome mea-
sures included costs, QALYs, life years gained (LYGs), and the amount of money
that can be spent per vaccination, while remaining cost-effective. RESULTS: Sig-
nificant excess RSV-associated deaths, hospitalisations, GP-visits and antibiotic
prescriptions were found. The burden of RSV increased with age and was higher for
high-risk (HR) elderly than for low-risk (LR) elderly. For several scenarios vaccina-
tion of the Dutch elderly appeared to be cost-effective. Using base-case assump-
tions, the amount of money that can be spent per vaccination, while remaining
cost-effective, ranged from €26 when vaccinating all 60 elderly to €68 when vac-
cinating only 85 elderly, for a willingness to pay of €50,000 per QALY and a vaccine
effectiveness of 70%. For HR-elderly only these estimates ranged from €52 to €99.
CONCLUSIONS: Vaccination of Dutch elderly with a hypothetical RSV vaccine was
found cost-effective for several scenarios. Vaccination is more likely to be cost-
effective when vaccinating only HR elderly than when vaccinating all elderly, de-
spite a decreased life expectancy and quality of life and a decreased effectiveness
of the vaccine assumed in HR-elderly in the model. This study shows the major
burden of RSV in the Dutch elderly, potential cost-effectiveness of vaccination,
stressing the need to have an effective vaccine available shortly.
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OBJECTIVES: Cases of genital warts (GW), caused by human papillomavirus (HPV),
remains a significant problem in the UK. Costs to the National Health Service (NHS)
to manage GW have been recently estimated, but studies excluded treatment by
General Practitioners (GP) and costed resources without inclusion of full staff time
and overheads thereby underestimating the full cost impact. This study estimates
the cost of GW management taking account of all identified GW cases seeking care
and applying the full NHS cost algorithm. METHODS: The number of GW cases
obtained from the surveillance of Genitourinary Medicine (GUM) clinics by Health
Protection Agency (HPA) and estimated number of GP visits (using THIN data) for
GW were combined and projected to 2010. The number of visits and therapy re-
quired for GW management were estimated by GUM experts for standard and
hard-to-treat patients. NHS payment by results (PbR) tariffs were applied to esti-
mate GUM resource costs and GP visit and therapy costs estimated from PSSRU and
BNF data. RESULTS: Extrapolating to 2010, there were 173,077 GUM clinic (33.5%
recurrent, 11% persistent) and 16,882 primary care GW episodes excluding referrals
to GUM. Approximately 2% of GUM cases were estimated to be hard-to-treat, re-
quiring additional visits and resources. Resulting NHS costs were £52.4 million
(average £273/female; £278/male patient). The proportion hard-to-treat was the
most sensitive variable for overall national costs.CONCLUSIONS:The £52.4 million
includes the full per patient costs for GUM clinics and costs for GP visits not previ-
ously estimated. This is higher than previous estimates and reflective of real NHS
costs. The full cost of GW management is important to understand and quantify
when considering the potential value of introducing a quadrivalent HPV vaccina-
tion in the UK. This is relevant from both a public health and health economic
perspective.
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OBJECTIVES: Surgical site infections (SSIs) are a significant burden to healthcare
systems negatively affecting Medicare reimbursement, quality and hospital repu-
tation. This study quantifies the economic impact of SSIs across multiple institu-
tions in the United States (US) using more up-to-date real-world data METHODS:
The economic impact of SSIs was evaluated in following surgeries (colon, hernia,
CABG, shunt, abdominal and vaginal hysterectomy, c-section, hip and knee pros-
thesis, spinal fusion, abdominoplasty and breast surgery). The data source was the
Premier Perspective™ Comparative Database, a national administrative discharge
database (2007-2010) from about 500 hospitals throughout the US. The SSIs were
identified by a combination of post-operative infection diagnosis codes, or postop-
erative prescription of selected antimicrobial drugs with treatment duration 5
days. The outcomes included rates of SSI by surgical category, the impact of SSI on
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